4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4 Lenvatinib Mesylate Intermediate Purity >98.0% (HPLC)

Short Description:

Name: 4-Amino-3-Chlorophenol Hydrochloride

CAS: 52671-64-4

Purity: >98.0% (HPLC) 

Appearance: Brown Solid Powder

Intermediate of Lenvatinib Mesylate CAS 857890-39-2

Contact: Dr. Alvin Huang  

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name 4-Amino-3-Chlorophenol Hydrochloride
Synonyms 2-Chloro-4-Hydroxyaniline Hydrochloride
CAS Number 618-89-3
CAT Number RF-PI1969
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C6H6ClNO·HCl
Molecular Weight 180.03 
Melting Point  254.0~256.0℃(dec.)(lit.)
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Brown Solid Powder
Purity / Analysis Method >98.0% (HPLC)  
Purity / Analysis Method 97.5~102.5% (Titration by AgNO3)  
Loss on Drying <0.50%
Residue on Ignition <0.30%
Total Impurities <2.00%
Infrared Spectrum Conforms to Structure
Proton NMR Spectrum Conforms to Structure
Test Standard Enterprise Standard
Usage Intermediate of Lenvatinib Mesylate (CAS: 857890-39-2)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

4-Amino-3-Chlorophenol Hydrochloride (CAS: 52671-64-4) is an intermediate of Lenvatinib Mesylate (CAS: 857890-39-2). Lenvatinib (trade name Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. Lenvatinib is used for the treatment of differentiated thyroid cancer that is either locally recurrent ormetastatic, progressive, and did not respond to treatment with radioactive iodine (radioiodine).LENVATINIB is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat thyroid cancer and kidney cancer. Compare kinase inhibitors. Lenvatinib is a multi-target inhibitor of VEGFR2 and VEGFR3 with IC50 of 4 nM and 5.2 nM, respectively.

  • Write your message here and send it to us